Raphael Nudelman, Ph.D., ERT, Teva Pharmaceuticals - Qepler Summits And Conferences

Raphael Nudelman, Ph.D., ERT

Director of Chemical & Computational Toxicology
Teva Pharmaceuticals
Israel
Teva Pharmaceutical Industries Ltd.

Raphael completed his Ph.D. in organic chemistry from the Weizmann Institute of Science in Israel, followed by postdoctoral positions in the US Air Force Research Lab in Aberdeen Proving Ground, Maryland USA and in Duke University Medical Center, North Carolina USA.

He joined Teva Pharmaceutical Industries’ Medicinal Chemistry department in 2003 and in 2010 he established the Chemical & Computational Toxicology group which he currently heads.

Raphael is a member of the American Chemical Society (ACS), the American Association of Pharmaceutical Scientists (AAPS), and of the Israel Chemical Society (ICS).

From 2011 to 2016, Raphael was the President of the Medicinal Chemistry Section of the Israel Chemical Society, and was as a Council member of the European Federation of Medicinal Chemistry (EFMC).

He is a member of the Advisory Council of High School Chemistry Education in the Israel Ministry of Education and a member of the Advisory Editorial Boards of Elsevier’s journal Drug Discovery Today: Technologies, and of Trends in Medicine and Health (TMH).

Related Sessions:

Genotoxic Impurities in
Pharmaceuticals Summit 2019

GTI strategies & new methodologies: analysis, in silico & regulations. Challenges & opportunities.
  • 11 Apr 2019
  • Berlin, DE
  • Pharma
Day 2: Friday, 12 April 2019
CASE STUDY: Best practice for dealing with conflicting computational predictions for mutagenicity.
  • Must we always take the conservative approach when dealing with conflicting predictions?
  • When can we overrule a predictions
  • Case studies showing methods to come to a consensus predictions
View Details

2nd Annual Genotoxic Impurities in
Pharmaceuticals Summit 2021

Genotoxic Impurities in Pharmaceuticals strategies & new methodologies: analysis, in silico & regulations.
  • 15 Jul 2021
  • Virtual,
  • Pharma
Day 1: Thursday, 15 July 2021
CASE STUDY: Setting limits for nitrosamines that lack carcinogenicity data.
View Details